Kineta, Inc. (NASDAQ:KA) Short Interest Down 99.3% in September

Kineta, Inc. (NASDAQ:KA) was the recipient of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 200 shares, a drop of 99.3% from the August 31st total of 28,500 shares. Based on an average daily volume of 600 shares, the short-interest ratio is currently 0.3 days.

Kineta Trading Down 4.8 %

NASDAQ KA opened at $0.60 on Friday. The stock has a market cap of $7.35 million, a P/E ratio of -0.40 and a beta of 0.46. Kineta has a fifty-two week low of $0.33 and a fifty-two week high of $5.39. The stock has a 50 day simple moving average of $0.65 and a two-hundred day simple moving average of $0.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.14 and a current ratio of 0.14.

Kineta (NASDAQ:KA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.20) EPS for the quarter.

Hedge Funds Weigh In On Kineta

A hedge fund recently bought a new stake in Kineta stock. PFG Investments LLC purchased a new position in Kineta, Inc. (NASDAQ:KA) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 326,988 shares of the company’s stock, valued at approximately $174,000. PFG Investments LLC owned approximately 2.67% of Kineta as of its most recent SEC filing. Hedge funds and other institutional investors own 30.32% of the company’s stock.

About Kineta

Kineta, Inc is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.